Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer

Research output: Contribution to journalArticle

Abstract

Background: This study sought to estimate the severity, etiology, and clinical importance of treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Methods: Serial lymphocyte counts and survival were analyzed retrospectively in 47 patients accounting for known prognostic factors. Results: Total lymphocyte counts (TLCs) were normal before therapy and did not change following neoadjuvant chemotherapy. Following radiation, TLC fell by 67% (median 500 cells/mm3, p <.00001). Multivariate analysis revealed an association between severe TLC and survival (HR 1.70, 95% CI: 0.8-3.6). Conclusions: Rapid and severe lymphopenia occurred in 50% of patients following radiation which was associated with reduced survival.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalCancer Investigation
Volume31
Issue number3
DOIs
StatePublished - Mar 1 2013

Keywords

  • Chemotherapy
  • Lymphopenia
  • Non-small-cell lung cancer
  • Radiation
  • Treatment-related toxicities

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this